Cipla
Pharmaceuticals and diagnostics | |
Revenue | ₹22,753 crore (US$2.8 billion) (FY23)[1] |
---|---|
₹5,027 crore (US$630 million) (FY23)[1] | |
₹2,802 crore (US$350 million) (FY23)[1] | |
Total assets | ₹23,662.56 crore (US$3.0 billion)[2] (2020) |
Total equity | ₹15,763.00 crore (US$2.0 billion)[2] (2020) |
Number of employees | 22,036[3] |
Subsidiaries | Invagen Pharmaceuticals |
Website | www.cipla.com |
Cipla Limited (stylized as Cipla) is an Indian
History
Cipla was founded in Mumbai in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories.[7][8] In July 1984, the name of the company was changed to 'Cipla'.[8]
Upon Hamied's death in 1972, his son Yusuf Hamied, a Cambridge-educated chemist, took over the company.
In 1995, Cipla launched Deferiprone, the world's first oral iron chelator.[7]
In 1999, Cipla joined the
During the avian flu pandemic in 2006, Cipla was able to reverse-engineer the drug Tamiflu and sell it for significantly lower prices.[9]
In 2013 Cipla acquired the South African company Cipla-Medpro. Its name was changed to Cipla Medpro South Africa Limited and was kept as a subsidiary.[12][13] At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third-biggest pharmaceutical company.[12] The company had been founded in 2002 under the name Enaleni Pharmaceuticals Ltd.[14] In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company;[15] in 2008, it changed its name to Cipla-Medpro.[16] In September 2023, it was announced Cipla South Africa had acquired the Midrand-headquartered healthcare products manufacturer, Actor Pharma.[17]
In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.[18]
In 2019 Cipla entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa.[19]
In April 2024, Cipla acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore. [20]
Products and services
Cipla sells
In July 2020, the company announced the introduction of
Operations
Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.[27][28] Exports accounted for 48% ₹4,948 crore (equivalent to ₹84 billion or US$1.1 billion in 2023) of its revenue for the 2013–14 fiscal year.[29] Cipla spent ₹517 crore (5.4% of their revenue) in the 2013–14 fiscal year on R&D activities.[29] The primary focus areas for R&D were development of new formulations, drug-delivery systems, and APIs. Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.
During the FY 2013–14, the company incurred ₹1,285 crore (equivalent to ₹21 billion or US$260 million in 2023) on employee benefit expenses.[29]
According to Cipla's 2022-23 annual report, the company had over 25,000 employees, out of which 14.3% were women.[3]
The equity shares of Cipla are listed on the
As of December 31, 2022, the promoter group, Y. K. Hamied and his family, held around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares.
Shareholders (as on 31-December-2022) | Shareholding[35] |
---|---|
Promoter Group | 33.61% |
Mutual funds | 14.09% |
Financial Institution/Banks/Insurance | 4.96% |
Foreign Institutional Investors (FII) | 28.39% |
Corporate Bodies | 0.53% |
Individuals | 14.72% |
NRIs/OCBs | 0.88% |
ADRs/GDRs | NIL |
Others | 2.82% |
Total | 100.00% |
Awards and recognitions
- In 1980, Cipla won Chemexcil Award for Excellence for exports.[36]
- In 2006, Cipla won Dun & Bradstreet American Express Corporate Awards.[37]
- In 2007, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies.[38]
- In 2012, Cipla received the Thomson Reuters India Innovation Award.[39]
- In 2015, Cipla stood third in the India's Most Reputed Brands (Pharmaceutical) list,[40] in a study conducted by BlueBytes,[41] a Media Analytics firm in association with TRA Research,[42] a brand insights organization (both part of the Comniscient Group).
Criticism
Emergency contraception
In August 2007, Cipla launched an
Generic drugs
In the late 1960s, Cipla began manufacturing a new, patented drug,
See also
References
- ^ a b c Jaiswar, Pooja Sitaram (12 May 2023). "Cipla Q4 results: Consolidated PAT at ₹526 cr, declares dividend". Mint. Retrieved 14 July 2023.
- ^ a b "Cipla Consolidated Balance Sheet, Cipla Financial Statement & Accounts". www.moneycontrol.com. Retrieved 28 July 2020.
- ^ a b "Business Responsibility Report 2013-14" (PDF). Cipla. 15 July 2014. Archived from the original (PDF) on 17 March 2015. Retrieved 17 September 2014.
- ^ "Know 10 largest Pharmaceutical Companies in India". Edu Dwar. Retrieved 28 July 2023.
- ^ "Cipla betting big on digitisation and emerging segments". The Economic Times. Retrieved 6 December 2022.
- ^ "Cipla betting big on digitisation and emerging segments". Financial Express. Retrieved 6 December 2022.
- ^ a b "About us - History". Cipla Limited. Archived from the original on 27 October 2015. Retrieved 3 November 2014.
- ^ a b "Company History - Cipla Ltd". Economic Times. Retrieved 3 November 2013.
- ^ )
- ^ "Introducing IPA- Indian Pharmaceutical Alliance". IPA, Indian Pharmaceutical Alliance. Retrieved 5 August 2023.
- ^ ISSN 0013-0389. Retrieved 5 August 2023.
- ^ a b Jawani, Lohit (16 July 2013). "Cipla completes acquisition of South Africa's Cipla Medpro". VC Circle. Archived from the original on 15 March 2016. Retrieved 8 September 2016.
- ^ "Delists from JSE". Business Day Live. 2013. Retrieved 13 July 2013.
- ^ "Enaleni Pharmaceuticals Limited Prospectus 2005". Morningstar. Retrieved 8 September 2016.
- ^ Avafia, Tenu; Berger, Jonathan; Hartzenberg, Trudi (2006). "The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries" (PDF). WHO. Archived from the original (PDF) on 23 January 2014.
- ^ Kahn, Tamar (10 September 2008). "South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro". All Africa.
- ^ Priyan, Vishnu (5 September 2023). "Cipla to bolster OTC portfolio with acquisition of Actor Pharma". Pharmaceutical Technology. Retrieved 5 September 2023.
- ISSN 0009-2347.
- ^ "Cipla's History". Cipla South Africa. n.d. Retrieved 16 May 2022.
- ^ "Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr". Business Standard India. Press Trust of India. 16 April 2024.
- ^ a b "cipla ltd (CIPLA:Natl India)". Business Week. Archived from the original on 6 November 2013. Retrieved 7 November 2013.
- ^ "Annual Report FY 2022-23" (PDF). Cipla.com. Cipla. 15 July 2014. Archived (PDF) from the original on 11 October 2023. Retrieved 11 October 2023.
- ^ "AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India" (Press release). PR Newswire. 8 August 2007. Retrieved 4 November 2013.
- ^ "India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug". Reuters. 21 June 2020.
- ^ "Coronavirus drug: Cipla launches Cipremi's, claims it is the cheapest Remdesivir". The Financial Express. 9 July 2020.
- ^ "Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt". businesstoday.in.
- ^ "Corporate Information: At a Glance". Cipla. Archived from the original on 12 September 2016. Retrieved 6 July 2019.
- ^ "Cipla in the pink of health". Business Standard. 25 September 2013. Retrieved 5 November 2013.
- ^ a b c d "Annual Report 2013-14" (PDF). Cipla. 22 August 2014. Archived from the original (PDF) on 22 January 2015. Retrieved 17 September 2014.
- ^ "Cipla Limited". BSEindia.com. Retrieved 2 November 2013.
- ^ "Scripwise Weightages in S&P BSE SENSEX". BSE India. Archived from the original on 1 December 2015. Retrieved 2 November 2013.
- ^ "NTPC Limited". NSE India. Retrieved 2 November 2013.
- ^ "Download List of CNX Nifty stocks (.csv)". NSE India. Retrieved 2 November 2013.
- ^ "StockEdge". web.stockedge.com. Retrieved 25 January 2023.
- ^ "Latest CIPLA Shareholding Pattern". Equitymaster. Retrieved 25 January 2023.
- ^ "Company Profile - Cipla Limited". IndiaInfoline.com. Retrieved 3 November 2013.
- ^ "Pharmaceutical sector award". Dun & Bradstreet. 10 September 2006. Archived from the original on 4 November 2013. Retrieved 3 November 2013.
- ^ "Asian Paints, Cipla in Forbes list". Economic Times. 17 November 2005. Retrieved 3 November 2013.
- ^ DBT, Cipla get Thomson Reuters India innovation awards
- ^ "Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list". The Economic Times. timesofindia.com. 17 August 2016. Retrieved 6 July 2019.
- ^ "Home". bluebytes.info.
- ^ "Home". trustadvisory.info.
- ^ "Cipla rises on morning-after pill". Hindustan Times. 5 October 2007. Archived from the original on 5 February 2015. Retrieved 3 November 2013.
- ^ "Cipla Launches i-pill". Financial Express. Retrieved 3 November 2013.
- ^ "'i-pill' by Cipla draws criticism from experts". Financial Express. 27 October 2007. Retrieved 3 November 2013.
- ^ a b "The Treasure of Mumbai". Wired Magazine. December 2006. Retrieved 4 November 2013.
- ^ "Heart-warming story of the Hamieds, who set up CIPLA and have been saving lives". National Herald. April 2020. Retrieved 12 April 2020.
- ^ "Indian Generic Drug Maker Targets Sad Americans". biohealthinvestor.com. 3 January 2007. Retrieved 4 November 2013.